Published

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in pharmacology
Date: 2017-01-01
Source: PubMed
DOI: 10.3389/fphar.2017.00974
PubMed: 29387009

Authors

Roseman L Nutt DJ Carhart-Harris RL

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Receptor Pharmacology Consciousness Mystical Experience Clinical Trial Randomized Controlled Trial Treatment-Resistant Depression Drug Interactions Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 10 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants2026-07-01 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARA2026-06-15 Human brain changes after first psilocybin use2026-05-05 Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis2026-04-01 Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD)2026-03-26 Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications2026-03-01 Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategy2025-12-01 Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models2023-09-01 Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience2021-09-01 Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.2017-01-01

Related papers

Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelicsFrontiers in Psychiatry · 2024-11-06 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01